The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00929864?cond=%22Arthritis%22&lup_s=07/28/2011&lup_d=30
